News List

Bharat Biotech unveils new brand identity; Donates Rs 1 crore worth vaccines to celebrate 20 Years of ‘Leading Innovation’

Over the last 20 years Bharat Biotech has a built a strong portfolio of more than 50 patents, 20+ commercially available safe, affordable and best in class vaccines and bio therapeutic products, accessible in over 100 countries.
By Team ABLE

Genome Valley based \"Clone-to-Clinic\" Indian biotechnology MNC, Bharat Biotech, unveiled its new corporate logo and its vision for the future. With its new logo and tag line ‘Lead Innovation’, the company is underlining its focus for developing new #madeinIndia molecules to prevent neglected diseases that affect large populace in the developing world. This new logo launch coincides with Bharat Biotech’s 20 years of excellence in Vaccine and bio therapeutics Innovation.

On its 20th year eve, the company committed to contribute INR 1 Crore worth of vaccines to Government of Telangana for its public health immunization. The commitment letter was handed over to the Hon’ble Minister Shri. KT Rama Rao, Cabinet Minister for IT E&C, MAUD, Industries & Commerce, Mines & Geology, Public Enterprises and NRI Affairs, Government of Telangana.

This year has been a double treat for Bharat Biotech family, as our 2 path breaking vaccines ‘Typbar TCV®’ and ‘ROTAVAC®’ getting global recognition and endorsement from World Health Organisation (WHO). These developments reinforce our foundation for the next stage of growth and endure to ‘Lead innovation’. Dr. Krishna Ella, Chairman and Managing Director, one of the pioneers in molecular research in India and the man behind the Knowledge Park at Genome Valley in Hyderabad said.

The new corporate logo –that symbolises lead innovation was launched by Shri. KT Rama Rao, followed by dedication of its two iconic vaccines ‘ROTAVAC® by Dr. T H Chowdary, Chairman Pragna Bharati and TypbarTCV® by celebrated media Industrialist Shri. Ramoji Rao, Chairman Ramoji Group.  The ceremony was conducted amidst the presence of industry luminaries, biotech stakeholders, eminent doctors & physicians, academic & scientific community, financial world & senior Government officials. .

In his address to the distinguished guests after unveiling Bharat Biotech new corporate logo and acknowledging the gesture of Bharat Biotech extending commitment to offer INR 1 Crore worth of ‘ROTAVAC® and TypbarTCV® vaccines to Government of Telangana Shri. KT Rama Rao said “Dr. Krishna Ella is passionate entrepreneur and a true patriot to name his company “Bharat” and being instrumental in making Hyderabad a Vaccine Capital of the World. He announced Telangana will soon have genome valley 2.0, to further strengthen its position as a global biotech destination. He also commended Bharat Biotech’s research accomplishments in the area of vaccines that impacted public health over the last 20 years and wished the company many more milestones.

“Our journey began 20 years ago and we have demonstrated our expertise in all activities required for an integrated biotech company. Our focus is on preventing infectious diseases and to reduce its public health impact,” Dr. Krishna Ella, said. The journey for Dr. Ella as the scientist turned entrepreneur began in 1995, when he started conceptualising a Hepatitis vaccine with an unheard price of $1 after returning from the US.

In her address Ms. Suchitra Ella, Co-Founder and Joint. Managing Director, Bharat Biotech said “Our focus is on vaccines and vaccinations, with the understanding that vaccines must reach the populations that need it the most, in order for them to become effective.”

“As co-founder of the company I was determined to build a socially-inclined enterprise along with Dr. Krishna Ella, and Bharat Biotech, is doing precisely that.

Bharat Biotech continues to adopt and instil new technologies at all levels of its molecule development right from bacteria/virus strain stage to research, clinical trials, development and thereafter manufacturing.  The company invests significant amount of funds in ensuring that its infrastructure is world class and meets global GMP standards.

Since it began its operations 20 years ago at Genome Valley, Bharat Biotech has emerged as a trusted vaccine research, development & manufacturing partner to governments, public health agencies, healthcare providers, delivering at global scale with highest degree of indigenisation capabilities, and leveraging advancements in new molecule research. Led by over 50 patents, a strong pipeline of vaccine brands that is accessible in over 100 countries Bharat Biotech is a uniquely integrated company that has built strong infrastructure to consolidate its leadership to make made in India vaccines for the world.

So, what is the goal ahead – Our goal is to ‘Lead Innovation’ and to consistently enable every populace in the emerging world to gain access to safer, world class vaccines at affordable cost. The target - ‘Mission 7 Billion’. Dr. Ella stated.